According to Sorrento Therapeutics 's latest financial reports the company's current EPS (TTM) is -$1.12. In 2022 the company made an earnings per share (EPS) of -$1.37 an increase over its 2021 EPS that were of -$1.45.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -$1.12 | -18.25% |
2022 | -$1.37 | -5.52% |
2021 | -$1.45 | 11.54% |
2020 | -$1.30 | -40.91% |
2019 | -$2.20 | 14.58% |
2018 | -$1.92 | -1576.92% |
2017 | $0.13 | -110.74% |
2016 | -$1.21 | -2.42% |
2015 | -$1.24 | -4.62% |
2014 | -$1.30 | -10.96% |
2013 | -$1.46 | 247.62% |
2012 | -$0.42 | 68% |
2011 | -$0.25 | -0% |
2010 | -$0.25 | -0% |
2009 | -$0.25 | |
2008 | N/A | -100% |
2007 | -$1.05 | 35.71% |
2006 | -$0.77 | -92.27% |
2005 | -$10.00 | 37132.85% |
2004 | -$0.02686 | -0% |
2003 | -$0.02686 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
Karyopharm Therapeutics
KPTI | -$1.32 | 17.86% | ๐บ๐ธ USA |
Exelixis EXEL | $0.28 | -125.29% | ๐บ๐ธ USA |